A New Dawn for Fragile Lives: Abeona Therapeutics' Zevaskyn Revenue Signals a Profound Shift

Sarepta's Shares Climb as Critical Safety Study for Elevidys Gene Therapy Kicks Off

ImmunityBio's Stock Plunge: Can Dr. Soon-Shiong's Cancer Science Convince Skeptical Investors?

The Ozempic War is Over: What the Novo Nordisk and Hims & Hers Settlement Means for Your Access to GLP-1s

A New Chapter for Psoriatic Arthritis: Bristol Myers Squibb's Sotyktu Wins Key FDA Approval

A Stinging Setback: Incyte's Cancer Therapy Fails to Clear FDA's High Bar

The Shifting Sands of Pharma: FDA's Grip, Global Ambitions, and the Future of Medicine

A Legal Storm Brews: Sarepta's Groundbreaking Muscular Dystrophy Therapy Faces Renewed Patent Challenge

A New Horizon for Schizophrenia Treatment

Moderna's Ambitious mRNA Flu Vaccine Hits a Regulatory Snag

A New Era for Flu Protection? Moderna's mRNA Vaccine on the Horizon

Hims & Hers' Super Bowl Cancer Test Ad Sparks Heated Debate Over Reliability and Ethics

A Pivotal Moment: Protalix Biotherapeutics Stands on the Cusp of a Game-Changing Decision for Elfabrio

Legend Biotech's Carvykti: A Beacon of Hope Reshaping Multiple Myeloma Treatment

Prime: Unlocking a Brighter Future for Wilson's Disease and Beyond

A New Dawn in Oncology: Grail's Quest for Multi-Cancer Early Detection

FDA Approval for Cytokinetics' Aficamten: A Scientific Triumph, But Wall Street Remains Wary

Cytokinetics' Myqorzo Secures Landmark FDA Approval, Reshaping HCM Treatment Landscape

Axogen's Avance Nerve Graft Achieves Historic FDA Biologics License Approval

Eli Lilly's Jaypirca Secures Full FDA Approval, Offering New Hope for Certain Blood Cancers

Citius Oncology's Lymphir: A New Chapter in the Fight Against Cutaneous T-Cell Lymphoma

A New Dawn for Skin Cancer Patients: Citius Oncology Launches Lymphir in the US

A Game-Changer for Kids' Eyes: New FDA-Approved Glasses Tackle Nearsightedness Head-On

A Welcome Return: FDA Gives Green Light to Reformulated Ranitidine (Zantac) After Major Recall

A New Horizon for SMA Patients: Novartis's Groundbreaking Gene Therapy Gets FDA Nod

Novartis Shares Soar as FDA Gives Landmark Nod to Zolgensma Gene Therapy for Teens and Adults

A New Horizon for Bladder Cancer Patients: FDA Approves Keytruda-Padcev Combo as First-Line Therapy

The Siren Song of 'Secret' Serums: Why Influencer-Pushed Peptides Could Be Perilous

The Market's Whispers: Unpacking Today's Corporate Buzz

A New Chapter for Little Stomachs: Ironwood's Linzess Opens Doors for Pediatric IBS Relief

A Breath of Fresh Air for Kids Living with IBS-C

The Zynity Enigma: When Innovation Meets Intense Scrutiny at the FDA

The High Stakes Game: Sarepta, Duchenne, and the Edge of Hope

The Tug-of-War Over Abortion Pill Access: New York Fights Back Against Texas Ruling

The Game Changer? America's FDA Just Gave the Nod to an Oral Weight Loss Drug, But What's the Catch?

A Bittersweet Wait: Immuron's Travelan Data Faces an Unexpected Delay

The Heartbreaking Maze: Why Medicare Must Rethink Its Stance on Alzheimer's Treatment

Unlocking Access: The FDA's Bold Move to Fast-Track Life-Saving Biosimilars

A Cruel Twist of Fate: Alzheimer's Hope Dawns, But Not for Everyone — Yet.